4 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Coordination Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer RiMO-301, Pembrolizumab, Radiation - Head and Neck Cancer, Head Cancer | Phase 2 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-08-01 | 2026-07-29 |
| Phase I Study of RiMO-401 With Radiation in Advanced Tumors RiMO-401 - Advanced Solid Tumor, Intratumoral Injection | Phase 1 | Terminated | Coordination Pharmaceuticals, Inc. | 5 | 2024-02-22 | 2025-09-17 |
| Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer RiMO-301 - Head Neck Cancer, Intratumoral Injection | Phase 1 / Phase 2 | Recruiting | Coordination Pharmaceuticals, Inc. | 16 | 2023-04-03 | 2025-09-17 |
| Phase I Study of CPI-300 in Patients With Advanced Tumors CPI-300 - Advanced Tumors | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 17 | 2021-06-15 | 2024-02-07 |
| Study of CPI-200 in Patients With Advanced Tumors CPI-200 - Advanced Solid Tumor | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 17 | 2019-07-01 | 2022-02-24 |
| Study of CPI-100 in Patients With Advanced Tumors CPI-100, Capecitabine - Advanced Tumors | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 36 | 2018-12-21 | 2022-07-20 |
| Phase I Study of RiMO-301 With Radiation in Advanced Tumors RiMO-301 - Advanced Tumors | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 32 | 2018-04-10 | 2025-09-15 |
Radiation (2) · Capecitabine (1) · Radiotherapy (1) · pembrolizumab (1)
United States (7)